{"id":"https://openalex.org/W1753771853","doi":"https://doi.org/10.1517/14728214.2015.1061502","title":"Emerging drugs for the treatment of myelofibrosis","display_name":"Emerging drugs for the treatment of myelofibrosis","publication_year":2015,"publication_date":"2015-07-08","ids":{"openalex":"https://openalex.org/W1753771853","doi":"https://doi.org/10.1517/14728214.2015.1061502","mag":"1753771853","pmid":"https://pubmed.ncbi.nlm.nih.gov/26153237"},"language":"en","primary_location":{"id":"doi:10.1517/14728214.2015.1061502","doi":"https://doi.org/10.1517/14728214.2015.1061502","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14728214.2015.1061502","pdf_url":null,"source":{"id":"https://openalex.org/S66445379","display_name":"Expert Opinion on Emerging Drugs","issn_l":"1472-8214","issn":["1472-8214","1744-7623"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Emerging Drugs","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5060196258","display_name":"Holly Lynn Geyer","orcid":"https://orcid.org/0000-0002-3963-2350","observed_orcids":["https://orcid.org/0000-0002-3963-2350"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Holly L Geyer","raw_affiliation_strings":["a 1 Mayo Clinic, Department of Hospital Internal Medicine , 13400 E Shea Blvd, AZ, USA","Mayo Clinic, Department of Hospital Internal Medicine, 13400 E Shea Blvd, AZ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"a 1 Mayo Clinic, Department of Hospital Internal Medicine , 13400 E Shea Blvd, AZ, USA","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]},{"raw_affiliation_string":"Mayo Clinic, Department of Hospital Internal Medicine, 13400 E Shea Blvd, AZ, USA","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5039057642","display_name":"Ruben A. Mesa","orcid":"https://orcid.org/0000-0001-5880-7972","observed_orcids":["https://orcid.org/0000-0001-5880-7972"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruben A Mesa","raw_affiliation_strings":["b 2 Mayo Clinic, Division of Hematology and Oncology, Department of Hematology and Medical Oncology , 13400 E Shea Blvd, Scottsdale, AZ, USA +1 480 301 8335 ; +1 480 301 4675 ; Mesa.ruben@mayo.edu","+1 480 301 4675","Mayo Clinic, Division of Hematology and Oncology, Department of Hematology and Medical Oncology, 13400 E Shea Blvd, Scottsdale, AZ, USA+1 480 301 8335"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"b 2 Mayo Clinic, Division of Hematology and Oncology, Department of Hematology and Medical Oncology , 13400 E Shea Blvd, Scottsdale, AZ, USA +1 480 301 8335 ; +1 480 301 4675 ; Mesa.ruben@mayo.edu","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]},{"raw_affiliation_string":"+1 480 301 4675","institution_ids":[]},{"raw_affiliation_string":"Mayo Clinic, Division of Hematology and Oncology, Department of Hematology and Medical Oncology, 13400 E Shea Blvd, Scottsdale, AZ, USA+1 480 301 8335","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.2342,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.1988417,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":97,"max":98},"biblio":{"volume":"20","issue":"4","first_page":"663","last_page":"678"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.9990000128746033},{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.9639999866485596},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.8999999761581421},{"id":"https://openalex.org/keywords/jak2-inhibitors","display_name":"JAK2 inhibitors","score":0.9470000267028809},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.9940000176429749},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.996999979019165},{"id":"https://openalex.org/keywords/hsp90-inhibitors","display_name":"Hsp90 inhibitors","score":0.8880000114440918},{"id":"https://openalex.org/keywords/hedgehog-pathway-inhibitors","display_name":"Hedgehog pathway inhibitors","score":0.9860000014305115},{"id":"https://openalex.org/keywords/pi3k-akt-mtor-inhibitors","display_name":"PI3K/AKT/mTOR inhibitors","score":0.8809999823570251},{"id":"https://openalex.org/keywords/antifibrotic-agents","display_name":"antifibrotic agents","score":0.9639999866485596},{"id":"https://openalex.org/keywords/telomerase-inhibitors","display_name":"telomerase inhibitors","score":0.9990000128746033},{"id":"https://openalex.org/keywords/splenomegaly","display_name":"splenomegaly","score":0.9440000057220459},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.828000009059906},{"id":"https://openalex.org/keywords/symptom-burden","display_name":"symptom burden","score":0.9259999990463257},{"id":"https://openalex.org/keywords/pro-tools","display_name":"Pro Tools","score":0.6759999990463257},{"id":"https://openalex.org/keywords/health-related-quality-of-life","display_name":"health-related quality of life","score":0.703000009059906}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9357332587242126},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.6770963072776794},{"id":"https://openalex.org/C2781107747","wikidata":"https://www.wikidata.org/wiki/Q1898104","display_name":"Myeloproliferative neoplasm","level":4,"score":0.5944045782089233},{"id":"https://openalex.org/C2776239401","wikidata":"https://www.wikidata.org/wiki/Q416451","display_name":"Azacitidine","level":5,"score":0.527668297290802},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.5031678080558777},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.4963913559913635},{"id":"https://openalex.org/C2781053155","wikidata":"https://www.wikidata.org/wiki/Q5251502","display_name":"Deferasirox","level":3,"score":0.4748977720737457},{"id":"https://openalex.org/C133925201","wikidata":"https://www.wikidata.org/wiki/Q188419","display_name":"Life expectancy","level":3,"score":0.44297534227371216},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4347935914993286},{"id":"https://openalex.org/C2777753580","wikidata":"https://www.wikidata.org/wiki/Q1441305","display_name":"Constitutional symptoms","level":3,"score":0.41872477531433105},{"id":"https://openalex.org/C2780240888","wikidata":"https://www.wikidata.org/wiki/Q6052586","display_name":"International Prognostic Scoring System","level":4,"score":0.41770240664482117},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40999385714530945},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.39551785588264465},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.34100770950317383},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.3397606611251831},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.184183269739151},{"id":"https://openalex.org/C2777799968","wikidata":"https://www.wikidata.org/wiki/Q185137","display_name":"Thalassemia","level":2,"score":0.14299127459526062},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.12379369139671326},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000465","descriptor_name":"Algorithms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008017","descriptor_name":"Life Expectancy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013163","descriptor_name":"Splenomegaly","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D055728","descriptor_name":"Primary Myelofibrosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D055728","descriptor_name":"Primary Myelofibrosis","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1517/14728214.2015.1061502","doi":"https://doi.org/10.1517/14728214.2015.1061502","is_oa":false,"landing_page_url":"https://doi.org/10.1517/14728214.2015.1061502","pdf_url":null,"source":{"id":"https://openalex.org/S66445379","display_name":"Expert Opinion on Emerging Drugs","issn_l":"1472-8214","issn":["1472-8214","1744-7623"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Emerging Drugs","raw_type":"journal-article"},{"id":"pmid:26153237","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26153237","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on emerging drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":84,"referenced_works":["https://openalex.org/W55085034","https://openalex.org/W84221740","https://openalex.org/W240698351","https://openalex.org/W266507365","https://openalex.org/W768971023","https://openalex.org/W852298772","https://openalex.org/W1064291997","https://openalex.org/W1421162947","https://openalex.org/W1545484310","https://openalex.org/W1612798501","https://openalex.org/W1754059962","https://openalex.org/W1963499482","https://openalex.org/W1974602590","https://openalex.org/W1975191078","https://openalex.org/W1975692560","https://openalex.org/W1977267072","https://openalex.org/W1978853026","https://openalex.org/W1981888767","https://openalex.org/W1985809519","https://openalex.org/W1989167457","https://openalex.org/W1991495650","https://openalex.org/W1999701140","https://openalex.org/W2000454853","https://openalex.org/W2003535009","https://openalex.org/W2008628163","https://openalex.org/W2009766779","https://openalex.org/W2010527821","https://openalex.org/W2018254868","https://openalex.org/W2025124131","https://openalex.org/W2029318538","https://openalex.org/W2029548336","https://openalex.org/W2029985592","https://openalex.org/W2032938314","https://openalex.org/W2045496640","https://openalex.org/W2046982014","https://openalex.org/W2048470652","https://openalex.org/W2049145190","https://openalex.org/W2049965335","https://openalex.org/W2051540735","https://openalex.org/W2052701304","https://openalex.org/W2053043159","https://openalex.org/W2054173545","https://openalex.org/W2056116861","https://openalex.org/W2059045913","https://openalex.org/W2070959673","https://openalex.org/W2071990094","https://openalex.org/W2072575368","https://openalex.org/W2075345073","https://openalex.org/W2079645940","https://openalex.org/W2079681891","https://openalex.org/W2087623186","https://openalex.org/W2088915934","https://openalex.org/W2091572860","https://openalex.org/W2092668959","https://openalex.org/W2093014059","https://openalex.org/W2093301943","https://openalex.org/W2105414227","https://openalex.org/W2115351357","https://openalex.org/W2117263216","https://openalex.org/W2121743767","https://openalex.org/W2122395736","https://openalex.org/W2127559749","https://openalex.org/W2129394254","https://openalex.org/W2130858966","https://openalex.org/W2138058759","https://openalex.org/W2141249732","https://openalex.org/W2142945941","https://openalex.org/W2143105159","https://openalex.org/W2149373649","https://openalex.org/W2154608911","https://openalex.org/W2157228274","https://openalex.org/W2166506757","https://openalex.org/W2170419109","https://openalex.org/W2209063367","https://openalex.org/W2294876123","https://openalex.org/W2364832988","https://openalex.org/W2404783736","https://openalex.org/W2462835116","https://openalex.org/W2549440460","https://openalex.org/W2550982834","https://openalex.org/W2554369085","https://openalex.org/W2556588269","https://openalex.org/W2557899850","https://openalex.org/W2588198729"],"related_works":["https://openalex.org/W4404833622","https://openalex.org/W4408300327","https://openalex.org/W3177409823","https://openalex.org/W1969620200","https://openalex.org/W4405315956","https://openalex.org/W2780688021","https://openalex.org/W3111490643","https://openalex.org/W7223363729","https://openalex.org/W2157477083","https://openalex.org/W2895839683"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Myelofibrosis":[1],"(MF)":[2],"is":[3,79,186],"a":[4,18,80],"myeloproliferative":[5],"neoplasm":[6],"associated":[7,36],"with":[8,95,182],"significant":[9],"disease":[10],"burden":[11,100],"composed":[12],"of":[13,24,41,52,91,110,124,172],"splenomegaly,":[14,37],"constitutional":[15],"symptoms":[16,93],"and":[17,43,70,72,126,167],"reduced":[19],"life":[20,42],"expectancy.":[21],"The":[22,170],"advent":[23],"targeted":[25,53,134],"treatments":[26,54],"has":[27],"provided":[28],"new":[29],"means":[30],"by":[31],"which":[32],"to":[33,85,115,129,139],"improve":[34,130],"MF":[35,78,119,200],"symptoms,":[38],"health-related":[39],"quality":[40],"even":[44],"mortality.":[45],"AREAS":[46],"COVERED:":[47],"We":[48,60],"discuss":[49],"the":[50,89,118],"spectrum":[51],"currently":[55],"under":[56,175],"investigation":[57],"for":[58,143,199],"MF.":[59],"furthermore":[61],"compare":[62,122],"their":[63],"effects":[64],"on":[65],"improving":[66],"anemia,":[67],"reducing":[68],"fibrosis":[69],"splenomegaly":[71],"enhancing":[73],"symptom":[74,99,120,131,144,201],"control.":[75,132],"EXPERT":[76],"OPINION:":[77],"complex":[81],"disorder,":[82],"partly":[83],"attributable":[84],"its":[86],"heterogeneity.":[87],"Although":[88],"severity":[90],"patient":[92],"correlates":[94],"risk":[96],"category,":[97],"high":[98],"may":[101],"also":[102],"be":[103,192],"observed":[104],"in":[105,180],"low-risk":[106],"patients.":[107],"Serial":[108],"use":[109],"PRO":[111],"tools":[112],"allows":[113],"clinicians":[114],"objectively":[116],"evaluate":[117],"burden,":[121],"efficacy":[123],"therapies":[125,173],"adjust":[127],"medications":[128],"Novel":[133],"agents":[135,166,190],"have":[136],"proven":[137],"superior":[138],"historic":[140],"treatment":[141,147,197],"regimens":[142],"management.":[145,202],"Promising":[146],"categories":[148],"include":[149],"JAK2":[150],"inhibitors,":[151,154,160,162,164],"histone":[152],"deacetylase":[153],"hypomethylating":[155],"agents,":[156],"heat":[157],"shock":[158],"protein-90":[159],"hedgehog":[161],"PI3-AKT-mTOR":[163],"antifibrosing":[165],"telomerase":[168],"inhibitors.":[169],"majority":[171],"remain":[174],"investigation,":[176],"either":[177],"alone":[178],"or":[179],"combination":[181],"other":[183],"treatments.":[184],"It":[185],"anticipated":[187],"that":[188],"these":[189],"will":[191],"increasingly":[193],"integrated":[194],"into":[195],"standard":[196],"algorithms":[198]},"counts_by_year":[{"year":2016,"cited_by_count":5}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}